Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

14.20 +0.06 (+0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,123,625
Open 14.14
Bid (Size) 13.91 (1)
Ask (Size) 14.34 (1)
Prev. Close 14.14
Today's Range 13.99 - 14.46
52wk Range 7.610 - 19.99
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
The company scrapped its hereditary angioedema drug due to safety issues. 
Via Investor's Business Daily
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace

Performance

YTD
+0.92%
+0.92%
1 Month
+4.26%
+4.26%
3 Month
+26.45%
+26.45%
6 Month
-13.78%
-13.78%
1 Year
+3.42%
+3.42%

More News

Read More
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study
Via Benzinga
FDA Lifts Clinical Hold On BioCryst's BCX9930 Program For Rare Blood Disorder
Via Benzinga
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold
Via Benzinga
US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Novavax, Upstart Holdings And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Via Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
Via Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
BioCryst Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Stocks Rally as Major Indexes Look to End Losing Streaks
Via Talk Markets
BioCryst Gets FDA Fast Track Designation For Bone Formation Disorder Candidate
Via Benzinga
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.